Dorsomorphin (Compound C): Precision AMPK and BMP Pathway Inhibition for Mechanistic Research

Executive Summary: Dorsomorphin (Compound C, SKU B3252) is a cell-permeable, reversible, ATP-competitive inhibitor of AMP-activated protein kinase (AMPK) with a Ki of 109 nM, demonstrating selectivity over related kinases such as PKA, PKC, and JAK3 (APExBIO). Its ability to block both AMPK and BMP/Smad signaling enables investigation of metabolic, autophagic, and differentiation pathways (Ren et al., 2025). Dorsomorphin suppresses downstream phosphorylation events, including 80% inhibition of ACC phosphorylation, and impedes autophagic proteolysis. In cell and animal models, it modulates iron metabolism by reducing hepatic hepcidin mRNA and increases serum iron. The compound is insoluble in water and ethanol but dissolves in DMSO at ≥8.49 mg/mL, and is deployed at 4–40 μM in vitro or 10 mg/kg i.p. in vivo. These properties make Dorsomorphin an indispensable tool for dissecting AMPK and BMP/Smad signaling in cancer, metabolic, and stem cell research (see comparative review).

Biological Rationale

AMP-activated protein kinase (AMPK) is a central energy sensor that regulates glucose uptake, lipid metabolism, and autophagy in eukaryotic cells. Dysregulation of AMPK is implicated in metabolic disorders, cancer, and muscle atrophy (Ren et al., 2025). Bone morphogenetic protein (BMP) signaling, via SMAD 1/5/8 phosphorylation, modulates cell differentiation, iron metabolism, and neural fate commitment. Dorsomorphin (Compound C) enables targeted, quantitative blockade of these pathways, supporting mechanistic dissection in disease models where AMPK and BMP/Smad axes intersect. The ability to combine AMPK and BMP inhibition in a single, well-characterized small molecule accelerates translational research in metabolic disease, autophagy, and stem cell biology (see strategic overview).

Mechanism of Action of Dorsomorphin (Compound C)

• ATP-Competitive AMPK Inhibition: Dorsomorphin binds the ATP-binding site of AMPK, competitively blocking kinase activity (Ki = 109 nM, 25°C, buffer pH 7.4) (APExBIO).
• Specificity: Selectivity is demonstrated over related kinases (PKA, PKC, JAK3) in direct kinase assays, with negligible inhibitory activity at concentrations up to 10 μM (dossier review).
• Suppression of Downstream Phosphorylation: In hepatocytes and HeLa cells, Dorsomorphin reduces acetyl-CoA carboxylase (ACC) phosphorylation by approximately 80% at 10 μM (APExBIO).
• BMP/Smad Pathway Inhibition: Blocks BMP4-induced phosphorylation of SMAD 1/5/8 with an IC50 of 0.47 μM, reducing heterotopic ossification and hepatic hepcidin mRNA (Ren et al., 2025).
• Autophagy Regulation: Inhibits AMPK-driven autophagic proteolysis and mitophagy, validated by reduced LC3II/I ratios and impaired mitochondrial quality control in skeletal muscle models.

Evidence & Benchmarks

• Dorsomorphin inhibits AMPK with a Ki of 109 nM in cell-free kinase assays (APExBIO, product page).
• 80% inhibition of ACC phosphorylation is observed in hepatocytes treated with 10 μM Dorsomorphin for 1 hour at 37°C (APExBIO).
• BMP4-induced SMAD 1/5/8 phosphorylation is suppressed with an IC50 of 0.47 μM in C2C12 myoblasts (Ren et al., 2025).
• In high-fat-diet-induced sarcopenic obesity mouse models, Dorsomorphin administration (10 mg/kg i.p.) reverses the beneficial effects of AMPK-activating agents on mitophagy and muscle mass (Ren et al., 2025).
• Dorsomorphin reduces hepatic hepcidin mRNA and increases serum iron in murine models, confirming in vivo BMP pathway inhibition (Ren et al., 2025).
• Promotes neural induction and self-renewal in human embryonic stem cells by blocking BMP signaling (APExBIO, product page).

Compared to this guide to Dorsomorphin's role in cell viability screens, our article expands on the compound’s dual signaling inhibition in vivo and its impact on mitochondrial quality control in muscle atrophy models.

Common Pitfalls or Misconceptions

• Dorsomorphin is not a pan-kinase inhibitor: It shows selectivity for AMPK and BMP/Smad, but is not suitable for general kinase inhibition (APExBIO).
• It does not activate AMPK: Dorsomorphin is a direct inhibitor; use activators such as AICAR for AMPK activation studies.
• Solubility is limited to DMSO: Compound is insoluble in water and ethanol; improper dissolution may affect assay reproducibility.
• Long-term storage of solutions is not recommended: Prepare fresh solutions prior to each experiment; do not store in aqueous buffers.
• Dorsomorphin does not differentiate between AMPK subunit isoforms: It inhibits all AMPK catalytic subunits equivalently.

Applications, Limits & Misconceptions

Dorsomorphin is validated for inhibition of AMPK activity in hepatocytes, HeLa cells, and C2C12 myoblasts, suppression of BMP4-induced SMAD phosphorylation, and induction of dorsalization in zebrafish embryos. It is a critical tool for dissecting autophagy regulation and iron metabolism modulation in cellular and animal models. However, the compound’s effects are limited to its selectivity profile; it is not suitable for studies requiring pan-kinase or isoform-specific inhibition. For workflows requiring AMPK activation or alternative BMP pathway modulation, other agents are recommended. In vivo, efficacy has been confirmed at 10 mg/kg i.p. in mouse models, with endpoints including hepcidin mRNA reduction and increased serum iron. To extend the context, this review focuses on mitochondrial quality control, whereas our article details the specific mechanistic benchmarks and experimental boundaries for Dorsomorphin.

Workflow Integration & Parameters

• Preparation: Dissolve Dorsomorphin in DMSO at concentrations ≥8.49 mg/mL with gentle warming and ultrasonic treatment (APExBIO).
• Recommended usage: 4–40 μM in cell culture; 10 mg/kg i.p. for animal studies.
• Storage: Store solid at −20°C. Prepare fresh solutions before use; avoid long-term storage.
• Controls: Include vehicle controls (DMSO only) and, where possible, AMPK-activating comparators.
• Readouts: Assess ACC phosphorylation, LC3II/I ratio for autophagy, hepcidin mRNA, and SMAD 1/5/8 phosphorylation as primary endpoints.

For more detailed protocol harmonization and troubleshooting, compare with this summary of Dorsomorphin's biochemical properties, which our article updates with new in vivo benchmarks and AMPK/PINK1/Parkin pathway insights.

Conclusion & Outlook

Dorsomorphin (Compound C, APExBIO B3252) remains a gold standard for selective, reversible inhibition of AMPK and BMP/Smad pathways in mechanistic research. Its well-characterized selectivity, dual pathway inhibition, and validated application in metabolic, autophagy, and neural differentiation models support reproducible, translatable research outcomes. Ongoing studies leverage Dorsomorphin to clarify the AMPK/PINK1/Parkin axis in muscle atrophy and to probe BMP-driven cellular differentiation. As new disease models and pathway interactions emerge, Dorsomorphin’s defined profile ensures continued relevance in advanced cell signaling research.